Awaiting development: Guidance and quality standards
Showing 1 to 10 of 337
| Title | Type |
|---|---|
| 12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510] | Technology appraisal guidance |
| Abatacept for treating active idiopathic inflammatory myopathies [TSID10095] | Technology appraisal guidance |
| Abdominal aortic aneurysm | Quality standard |
| Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833] | Technology appraisal guidance |
| Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389] | Technology appraisal guidance |
| Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156] | Technology appraisal guidance |
| Acne | Quality standard |
| Adalimumab for treating early Dupuytren's contracture [ID6276] | Technology appraisal guidance |
| Adrenal dysfunction | Quality standard |
| Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care | Quality standard |